Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the ...

A breakthrough in cancer treatment may soon change how some of the most aggressive tumors are managed. A small, ...

A new PET radiotracer can effectively visualize Nectin-4, an emerging biomarker found in triple-negative breast cancer (TNBC). According to research published in the March issue of The Journal of ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors. IPH4502 demonstrated preclinical anti-tumor ...

Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal ...